Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.
about
Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimensLife expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesSafety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteersAIDS-defining illnesses among patients with HIV in Singapore, 1985 to 2001: results from the Singapore HIV Observational Cohort Study (SHOCS)Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort studyStructure-Based Design, Synthesis, and Structure−Activity Relationship Studies of HIV-1 Protease Inhibitors Incorporating PhenyloxazolidinonesSubstrate Envelope-Designed Potent HIV-1 Protease Inhibitors to Avoid Drug ResistanceDesign, Synthesis, and Biological and Structural Evaluations of Novel HIV-1 Protease Inhibitors To Combat Drug ResistanceAdherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in BotswanaEffects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected personsWork-related barriers and facilitators to antiretroviral therapy adherence in persons living with HIV infectionInflammation, coagulation and cardiovascular disease in HIV-infected individualsGenetic and genomic architecture of the evolution of resistance to antifungal drug combinationsRelationship between food insecurity and mortality among HIV-positive injection drug users receiving antiretroviral therapy in British Columbia, CanadaIllicit drug use is a significant risk factor for loss to follow up in patients with HIV-1 infection at a large urban HIV clinic in TokyoGender inequities in quality of care among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010)HIV/AIDS epidemiology, pathogenesis, prevention, and treatmentInfluence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies.Changes in the prevalence of HIV-associated mucosal disease at a dedicated clinic over 7 years.Life expectancy after HIV diagnosis based on data from the counseling center for behavioral diseases.Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational studyAboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART.Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda.Comparison of emergency department HIV testing data with visit or patient as the unit of analysisRisk and prognostic significance of tuberculosis in patients from The TREAT Asia HIV Observational DatabaseInhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal herbal plantsMortality after hospitalization for pneumonia among individuals with HIV, 1995-2008: a Danish cohort studyLongitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion.Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM developmentAlcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes.Provider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIVPatient-level moderators of the efficacy of peer support and pager reminder interventions to promote antiretroviral adherence.Contraceptive use and method preference among women in Soweto, South Africa: the influence of expanding access to HIV care and treatment servicesYouth, unemployment, and male gender predict mortality in AIDS patients started on HAART in Nigeria.Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimensMethadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug usersAssociations among correlates of schedule adherence to antiretroviral therapy (ART): a path analysis of a sample of crack cocaine using sexually active African-Americans with HIV infection.Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive statusDrug use and medication adherence among HIV-1 infected individuals.Modeling the cost-effectiveness of HIV treatment: how to buy the most 'health' when resources are limited.
P2860
Q24534391-23B12139-9D7F-453A-9FA3-0E13833148AEQ24597052-44EC7E80-43DF-4FC9-97B0-36F660F6E65CQ24673149-464094EB-A043-4575-B34A-FBF2A8460F32Q24802044-C437BDC9-7788-4111-A817-4C3E249100FDQ24811445-4B8C9ED8-37A6-4000-BF4B-8E2DC366C9C1Q27665164-B884DF03-3E79-4D07-8772-FD222337DCC9Q27679880-B0D88D91-1EA8-4EF4-AB16-F974EBD8FBB3Q27681219-EA6382E4-2240-4A6B-A6B3-9BB6B50D6785Q28221847-3D9FE984-8012-452B-B355-BBFFBE171312Q28353070-D53564C6-8AE3-4751-8ABD-76ADB02BF7FAQ28389395-EF770E58-FA36-423D-99C7-7E947537DC14Q28483645-1CBDC83C-384C-42A1-A1C1-6247957B33D4Q28486002-07276C68-DD3A-45CB-9DF3-E041BA76066DQ28533313-9778C7A0-7063-4960-A37B-EBD63FF61D57Q28535181-AB06138C-F165-4816-BD9C-4F9349D272B4Q28541096-34D0C58C-B450-4803-AD6D-74B9D283E85DQ30356074-C5116BAE-FA08-41C7-89BF-B0566FEA2799Q30453160-CC7AF0F8-3F5A-4213-A896-7D1C719AE279Q30482332-851E0CA7-1C00-4DAD-84FC-793AC700F3CDQ30756408-4C5B5897-E241-4E98-8501-63AD34039929Q30781344-C45E1DC1-0499-4C9C-94EE-04CDAD200F9EQ33244605-F5A318AC-F626-4A03-987C-2537BDC16433Q33385849-63DAEE3E-7B41-4303-A97E-8F185A3B7C3BQ33427350-CCD66D16-6C37-4734-A165-F52255631D40Q33433188-070C738E-05AE-4F96-BD0E-ED9469D58803Q33490833-E54F5450-9F54-4A1A-B802-A895FF1DD2DEQ33502708-CDA37309-7F89-404A-B666-3F80BC965203Q33563564-CF21E3B4-08D4-4630-8710-C05F7A3821FCQ33564397-6A0B58DC-4FD6-41FD-AE39-5948D4CC66C2Q33660210-740DE79D-7B53-40D3-BDAB-D5662E296AD3Q33703513-D626382F-4AE9-44D0-98C5-61D40F570BFEQ33707680-7DDC052B-3205-4B1B-90AC-9348FF1E94E7Q33747752-194BC090-1090-42D0-8F65-B724E7732001Q33769809-1E89089A-1921-4A81-B3F4-FF4E6DAA779CQ33798351-FD7A749E-078C-41DD-A8B7-862DC1387437Q33802147-AA2C1D70-41A7-40A2-94AD-5B7870DE6FF5Q33814884-D9003313-5C20-4058-B0ED-E9A887678326Q33827543-A69AED59-2684-4FF1-8F01-C2BA9C4A94D0Q33841530-7C741748-052E-4C41-9470-E5D3ECEFECD9Q33854542-D8A8AAAA-06E1-485C-8033-FED31E64DF87
P2860
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Improved survival among HIV-in ...... ion of antiretroviral therapy.
@en
Improved survival among HIV-in ...... ion of antiretroviral therapy.
@nl
type
label
Improved survival among HIV-in ...... ion of antiretroviral therapy.
@en
Improved survival among HIV-in ...... ion of antiretroviral therapy.
@nl
prefLabel
Improved survival among HIV-in ...... ion of antiretroviral therapy.
@en
Improved survival among HIV-in ...... ion of antiretroviral therapy.
@nl
P2093
P356
P1476
Improved survival among HIV-in ...... ion of antiretroviral therapy.
@en
P2093
J S Montaner
M V O'Shaughnessy
P304
P356
10.1001/JAMA.279.6.450
P407
P577
1998-02-01T00:00:00Z